Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
… 2.7 MB Sep 3, 2025 10:00 AM EDT Biogen Thematic Pipeline Seminar: Lupus Listen to webcast Biogen Thematic Pipeline Seminar: Lupus 2.5 MB Jul 31, 2025 8:30 AM EDT Q2 … 2.7 MB Sep 3, 2025 10:00 AM EDT Biogen Thematic Pipeline Seminar: Lupus Listen to webcast Biogen Thematic …
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026 - … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement …
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026 - … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and …
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
March 28, 2026 - … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and …
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
March 20, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
March 19, 2026 - … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and …
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026 - … of SMA; the potential of our commercial business and pipeline programs, including salanersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of SMA; the potential of our commercial business and pipeline programs, including salanersen; and risks and …
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
March 5, 2026 - … arrangements; the potential of our commercial business and pipeline programs, including Biogen’s SMA research programs; … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including Biogen’s SMA research programs; …
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
March 4, 2026 - … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and …
Biogen Announces Board Chair Transition
February 11, 2026 - … and to support the advancement of the Company’s renewed pipeline. Her extensive scientific background, encompassing … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment … the impact from potential tariffs; productivity of our R&D pipeline, collaborations, and business development …
